Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway - Yousefi, Keyvan; Irion, Camila I.; Takeuchi, Lauro M.; Ding, Wen; Lambert, Guerline; Eisenberg, Trevor; Sukkar, Sarah; Granzier, Henk L.; Methawasin, Mei; Lee, Dong I.; Hahn, Virginia S.; Kass, David A.; et al. (Journal of the American College of Cardiology, 2019)
Keywords: Alport syndrome; Animals; Autoantigens - genetics; Bioenergetics; Cardiology; Cardiomyocytes; Cardiomyopathy; Cardiovascular; Collagen Type IV - genetics; Congestive heart failure; Coronary artery disease; Cytokines; Disease Models, Animal; Edema; Fibrosis; Flow velocity; Genetic Therapy; Genotype & phenotype; Heart failure; Heart Failure, Diastolic - etiology; Heart Failure, Diastolic - metabolism; Heart Failure, Diastolic - pathology; Heart Failure, Diastolic - therapy; HFpEF; Hip; hiPS-CM; Hypertension; Hypertrophy; Intermediates; Ketoglutarate Dehydrogenase Complex - genetics; Ketoglutarate Dehydrogenase Complex - metabolism; Ketoglutaric acid; Kidney diseases; Lung diseases; Mice; Mice, Knockout; Mitochondria; Mitochondria - metabolism; mRNA; Myocardium - metabolism; Myocardium - pathology; Nephritis, Hereditary - complications; OGDHL; Osteopontin; Osteopontin - genetics; Osteopontin - metabolism; Oxidative Stress; Oxoglutarate dehydrogenase (lipoamide); Patients; Phenotypes; Pluripotency; Pulmonary arteries; Renal failure; Renal function; Stem cells; Therapeutic applications; Ventricle; Ventricular Dysfunction, Left - etiology; Ventricular Dysfunction, Left - metabolism; hiPS-CM; hiPSC; osteopontin; mitochondria; Alport syndrome; OGDHL; CM; HFpEF; OPN; HFrEF; IVRT; isovolumetric relaxation time; cardiac myocyte; heart failure with preserved ejection fraction; 2-oxoglutarate dehydrogenase-like; heart failure with reduced ejection fraction; human-induced pluripotent stem cell